Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01814501 · ClinicalTrials.gov registry record · Phase 2
Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab
A Phase 2 study of Recurrent Colon Cancer and Recurrent Rectal Cancer, sponsored by John Hays.
- Completed
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
- 2
- Study locations
NCT01814501 is a Phase 2 study of Recurrent Colon Cancer and Recurrent Rectal Cancer that has completed, run by John Hays. The registered enrollment target is 16 participants, below the 29-participant average among 10 other Recurrent Colon Cancer trials with a reported enrollment target (45% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT01814501, a Phase 2 study of Recurrent Colon Cancer and Recurrent Rectal Cancer, has completed, sponsored by John Hays.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
- 2
- Study locations
Study Summary
This phase II trial studies how well panitumumab and combination chemotherapy works in treating patients with metastatic colorectal cancer previously treated with combination chemotherapy and bevacizumab. Monoclonal antibodies, such as panitumumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy, such as leucovorin calcium, fluorouracil, and irinotecan hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving panitumumab and combination chemotherapy together may kill more tumor cells
Conditions Studied
Interventions
- DRUG fluorouracil
- DRUG leucovorin calcium
- DRUG irinotecan hydrochloride
- BIOLOGICAL panitumumab
Study Locations (2)
Ohio
- Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center - Columbus
Tennessee
- Vanderbilt-Ingram Cancer Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2013-02-01 |
| Est. Completion | 2018-08-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01814501
The ClinicalTrials.gov registry entry for NCT01814501 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 29-participant average among 10 other Recurrent Colon Cancer trials with a reported enrollment target (45% lower). The listed sponsor is John Hays, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 8 conditions, with Recurrent Colon Cancer appearing as the primary indexed condition, and to 4 interventions - of which fluorouracil is the first listed.
NCT01814501 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Ohio, Tennessee.
Frequently Asked Questions
What is clinical trial NCT01814501 about?
NCT01814501 is a clinical study titled "Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab". This phase II trial studies how well panitumumab and combination chemotherapy works in treating patients with metastatic colorectal cancer previously treated with combination chemotherapy and bevacizumab. Monoclonal antibodies, such as panitumumab, can block tumor growth in different ways. Some bloc...
What is the current status of trial NCT01814501?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2013-02-01. Estimated completion is 2018-08-06.
What conditions does trial NCT01814501 study?
This clinical trial studies the following conditions: Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IV Colon Cancer, Stage IV Rectal Cancer, Mucinous Adenocarcinoma of the Colon.
What interventions are being tested in trial NCT01814501?
The interventions under investigation include: fluorouracil (DRUG), leucovorin calcium (DRUG), irinotecan hydrochloride (DRUG), panitumumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT01814501?
This trial is sponsored by John Hays, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01814501 being conducted?
This trial has 2 study locations across Ohio, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Colon Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Azacitidine and Entinostat in Treating Patients With Metastatic Colorectal Cancer
COMPLETED · Phase 2
-
Bevacizumab and Cetuximab With or Without Irinotecan in Treating Patients With Irinotecan-Refractory Metastatic Colorectal Cancer
COMPLETED · Phase 2
-
2 Phase Comparison of Pre-operative CT and PET Images for Metastatic Colorectal Cancer
COMPLETED · Phase 2
-
Cetuximab and Everolimus in Treating Patients With Metastatic or Recurrent Colon Cancer or Head and Neck Cancer
COMPLETED · Phase 1
-
18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy
COMPLETED · Phase 1
-
Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Recurrent or Persistent Metastatic Colorectal Cancer
COMPLETED · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.